Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | PRKACA | P17612 | 2/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.65 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387031 | 0.93 | KDM4E (0.74) | KDM4ETSHRMAPTALDH1A1LMNA | |
| SCHEMBL11890502 | 0.93 | KDM4E (0.73) | KDM4ETSHRMAPTPRKACARPS6KB1 | |
| SCHEMBL5037311 | 0.93 | KDM4E (0.70) | KDM4ETSHRMAPTPRKACARPS6KB1 | |
| SCHEMBL1386481 | 0.91 | KDM4E (0.71) | KDM4ETSHRPRKACARPS6KB1GSK3B | |
| SCHEMBL1385523 | 0.91 | KDM4E (0.71) | KDM4ETSHRMAPTALDH1A1LMNA | |
| SCHEMBL1900960 | 0.89 | KDM4E (1.00) | KDM4ETSHRMAPTALDH1A1LMNA | |
| SCHEMBL1386316 | 0.88 | BCHE (0.68) | KDM4ETSHRMAPTLMNAPRKACA | |
| SCHEMBL5041207 | 0.87 | KDM4E (0.65) | KDM4ETSHRMAPTALDH1A1 | |
| SCHEMBL2581813 | 0.87 | KDM4E (0.68) | KDM4ETSHRMAPTPRKACARPS6KB1 | |
| SCHEMBL1899190 | 0.87 | KDM4E (0.82) | KDM4ETSHRMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4829791-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | claimed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | claimed |
| JP-2006528238-A | — | — | 2006-12-14 | — | — | JP | claimed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | claimed |
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2019-01-10 | — | — | US | disclosed |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG | 2018-12-20 | — | — | US | disclosed |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2018-06-26 | — | — | US | disclosed |
| WO-2012098203-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT1S1, AKT2 | KDM4E 3884/4885TSHR 818/4885MAPT 4619/4885 |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB, TUBB1, TUBB6 | KDM4E 4206/4885TSHR 4340/4885MAPT 54/4885 |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | TUBB, TUBB1, TUBB6 | KDM4E 4206/4885TSHR 4340/4885MAPT 54/4885 |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | KDM4E 3884/4885TSHR 818/4885MAPT 4619/4885 |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB1, TUBB, TUBB6 | KDM4E 3837/4885TSHR 4281/4885MAPT 80/4885 |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BUB1B, BUB1, BUB3 | KDM4E 2211/4885TSHR 2717/4885MAPT 2809/4885 |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT2, AKT1S1 | KDM4E 4613/4885TSHR 3124/4885MAPT 2226/4885 |
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | KDM4E 1039/4885TSHR 1025/4885MAPT 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.